Clinicians often hope that adding newer diabetes therapies can simplify treatment regimens for their patients. Specifically, many physicians wonder if starting a glucagon-like peptide-1 receptor agonist (GLP-1RA) allows for safe insulin discontinuation. However, a recent target trial emulation suggests this clinical hope might not align with real-world outcomes. Ultimately, managing complex insulin regimens remains a major challenge for both providers and patients. Consequently, finding an effective clinical pathway to reduce or stop insulin therapy is highly desirable. Therefore, this trial evaluated whether GLP-1RAs offer a unique advantage over oral glucose-lowering agents in achieving this goal.
The Real-World Study Design
The researchers utilized extensive electronic health record data from the U.S. Veterans Health Administration. Specifically, they analyzed 8,869 matched sets of patients with type 2 diabetes receiving basal insulin. These participants initiated treatment with either a GLP-1RA, an SGLT-2i, or a DPP-4i between 2020 and 2022. Additionally, the investigators defined the primary outcome as a gap in insulin prescription fills of 12 months or longer. Furthermore, nearly half of the cohort had a baseline HbA1c level of 9% or higher. Consequently, this study represented a real-world population with significant glycemic challenges.
Comparing Insulin Discontinuation Across Drug Classes
Surprisingly, the clinical data showed no differences in discontinuation rates among the three drug groups over three years. For example, 16.7% of patients in the GLP-1RA group successfully stopped their basal insulin. Meanwhile, 17.9% of SGLT-2i initiators and 17.1% of DPP-4i initiators achieved the same outcome. Therefore, adding a GLP-1RA did not increase the likelihood of stopping insulin compared to using oral agents. Moreover, subgroup analyses showed no comparative advantage for GLP-1RAs in any specific patient population. Clinicians should therefore manage expectations when adding these therapies. Although GLP-1RAs offer stellar cardiorenal and weight-loss benefits, they do not guarantee an easy path away from insulin.
Clinical Implications for Indian Practitioners
In India, the burden of type 2 diabetes remains high, and cost-effectiveness plays a critical role in prescribing patterns. Although GLP-1RAs are transforming diabetes care globally, their high cost often presents a significant barrier in resource-limited clinical settings. Consequently, Indian clinicians must carefully weigh the financial implications against the expected clinical benefits. Additionally, since this study shows no superior benefit of GLP-1RAs for stopping insulin, cheaper oral options remain highly attractive alternatives. Therefore, physicians should prioritize individualized goals rather than expecting routine insulin cessation when prescribing these advanced therapies.
Frequently Asked Questions
Q1: Did adding GLP-1 RAs to basal insulin increase the chances of insulin discontinuation compared to SGLT-2is or DPP-4is?
No, the study showed that GLP-1RAs did not increase stopping rates compared to oral therapies over three years.
Q2: What was the primary definition of insulin discontinuation in this trial?
The researchers defined discontinuation as a gap in insulin prescription fills of 12 months or longer.
Q3: Should clinicians stop prescribing GLP-1RAs to patients who are on basal insulin?
No, clinicians should still use GLP-1RAs for their cardiovascular and renal benefits. However, they should not expect automatic insulin cessation.
References
- Lipska KJ et al. Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation. Ann Intern Med. 2026 Jul 14. doi: 10.7326/ANNALS-25-05216. PMID: 42441965.